STOCK TITAN

Novavax, Inc. - NVAX STOCK NEWS

Welcome to our dedicated news page for Novavax (Ticker: NVAX), a resource for investors and traders seeking the latest updates and insights on Novavax.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Novavax's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Novavax's position in the market.

Rhea-AI Summary
Novavax, Inc. (NVAX) to participate in TD Cowen's 44th Annual Health Care Conference, featuring fireside chat and investor meetings on March 6, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.11%
Tags
conferences
-
Rhea-AI Summary
Novavax, Inc. (NVAX) achieved revenues of $291 million in Q4 2023 and $1.0 billion for full year 2023. The company is progressing towards a Phase 3 COVID-19-Influenza Combination vaccine trial in 2024 with a potential 2026 launch. Novavax rescaled its global footprint with a 30% headcount reduction compared to Q1 2023, settled with Gavi, and provided a revenue guidance of $800 million to $1 billion for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-26.74%
Tags
earnings
-
Rhea-AI Summary
Novavax, Inc. (NVAX) and Gavi, the Vaccine Alliance, settle the 2021 Advance Purchase Agreement related to NVX-CoV2373, Novavax's COVID-19 vaccine prototype. Novavax makes a $75 million initial payment to Gavi and agrees to deferred payments of $80 million annually through 2028, totaling up to $400 million. The agreement aims to ensure equitable access to vaccines for vulnerable populations in lower income countries.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.61%
Tags
covid-19
Rhea-AI Summary
Novavax, Inc. (NVAX) will announce its Q4 and full-year 2023 financial results and operational highlights on February 28, 2024. The conference call details and webcast information are provided for participants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
conferences earnings
-
Rhea-AI Summary
Novavax, a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, announced its participation in the 42th Annual J.P. Morgan Healthcare Conference. The conference will include a presentation and Q&A session on January 8, 2024, with John C. Jacobs, President and Chief Executive Officer, as a participant. A replay of the recorded presentation and Q&A will be available on the company's website for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
conferences
-
Rhea-AI Summary
Novavax, Inc. (NVAX) announced that the Taiwan Food and Drug Administration has granted emergency use authorization for Nuvaxovid™ XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601) for active immunization to prevent COVID-19 in individuals aged 12 and older. The updated vaccine will be widely available at vaccination centers across Taiwan. The authorization was based on non-clinical data showing that Novavax's updated COVID-19 vaccine induced functional immune responses for various variants. Novavax's updated COVID-19 vaccine is also authorized in the U.S., the European Union, Canada, and by the World Health Organization, and is under review in other markets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.44%
Tags
acquisition covid-19
Rhea-AI Summary
Novavax, Inc. (Nasdaq: NVAX) announces expanded authorization for Nuvaxovid™ XBB.1.5 Vaccine in Canada for individuals aged 12 and older. The vaccine targets immune-evasive variants of SARS-CoV-2 and has shown to induce functional immune responses against multiple variants. Novavax's updated COVID-19 vaccine is also authorized in the U.S., the European Union, and by the WHO, and is under review in other markets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.18%
Tags
covid-19
-
Rhea-AI Summary
Novavax, Inc. (NVAX) announced that its Nuvaxovid™ XBB.1.5 COVID-19 Vaccine has been granted Emergency Use Listing (EUL) by the World Health Organization for active immunization to prevent COVID-19 in individuals aged 12 and older. The vaccine can be stored at 2 to 8 degrees Celsius and has a 12-month shelf life. The EUL was based on non-clinical data showing that the vaccine induced functional immune responses against various COVID-19 variants. The vaccine is authorized in the U.S. and the European Union, and is under review in other markets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.95%
Tags
covid-19
-
Rhea-AI Summary
Novavax, Inc. (Nasdaq: NVAX) announces a new organizational structure for its executive leadership team aimed at enhancing focus on strategic priorities and continuing the evolution of the Company's scale and structure. John Trizzino appointed as President and Chief Operating Officer to lead commercial, CMC, and regulatory functions. Mark Casey to join as Chief Legal Officer and Corporate Secretary.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.72%
Tags
management
Rhea-AI Summary
Novavax, Inc. (Nasdaq: NVAX) to Participate in Jefferies London Healthcare Conference, Fireside Chat with CEO and President, Investor Meetings, and Recorded Session Available
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7%
Tags
conferences
Novavax, Inc.

Nasdaq:NVAX

NVAX Rankings

NVAX Stock Data

640.28M
125.25M
4.93%
56.22%
46.15%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Gaithersburg

About NVAX

novavax, inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. our recombinant nanoparticles and matrix-m™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. product pipeline our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus ("rsv"​), seasonal influenza, pandemic influenza, and ebola virus ("ebov"​). we have additional preclinical-stage programs for a variety of infectious diseases. corporate overview novavax is headquartered in gaithersburg, maryland with additional facilities in rockville, maryland and uppsala, sweden. novavax is traded on the nasdaq stock market under the symbol nvax and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.